Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice

We cloned a rat vascular chymase (RVCH) from smooth muscle cells (SMCs) that converts angiotensin I to II and is up-regulated in SMC from spontaneously hypertensive vs. normotensive rats. To determine whether increased activity of RVCH is sufficient to cause hypertension, transgenic mice were generated with targeted conditional expression of RVCH to SMC, with the use of the tetracycline-controlled transactivator (tTA). We confirmed conditional expression of RVCH by mRNA, protein, and chymase activity in the absence, but not in the presence, of dietary doxycycline. The systolic blood pressure (mmHg), measured by carotid artery cannulation at 10–12 weeks of age, was higher in tTA+/RVCH+ mice than in nonbinary transgenic littermates (136 ± 4 vs. 109 ± 3) (P < 0.05), as were the diastolic and mean pressures. Hypertension was completely reversed by doxycycline, suggesting a causal link with chymase expression. Medial thickening of mesenteric arteries from tTA+/RVCH+ mice vs. littermates (0.82 ± 0.1 vs. 0.42 ± 0.02) (P < 0.05) was associated with increased SMC proliferation, as judged by positive immunoreactivity, with the use of an antibody to the proliferating cell nuclear antigen. These structural changes were prevented by doxycycline. Perfusion myography of mesenteric arteries from tTA+/RVCH+ mice also revealed increased vasoconstriction in response to phenylephrine and impaired metacholine-induced vasodilatation when compared with littermate controls or with the doxycyline-treated group. Our studies suggest that up-regulation of this vascular chymase is sufficient to cause a hypertensive arteriopathy, and that RVCH may be a candidate gene and a therapeutic target in patients with high blood pressure.

[1]  E. Olson,et al.  Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells , 1996, The Journal of cell biology.

[2]  S. Takai,et al.  Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. , 1999, Circulation.

[3]  C. Boulanger,et al.  Secondary endothelial dysfunction: hypertension and heart failure. , 1999, Journal of molecular and cellular cardiology.

[4]  B. Conklin,et al.  Conditional expression and signaling of a specifically designed Gi-coupled receptor in transgenic mice , 1999, Nature Biotechnology.

[5]  G. Angelini,et al.  Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. , 2000, Circulation.

[6]  D. Woolley,et al.  MAST CELL DISTRIBUTION, ACTIVATION, AND PHENOTYPE IN ATHEROSCLEROTIC LESIONS OF HUMAN CAROTID ARTERIES , 1997, The Journal of pathology.

[7]  E. Schiffrin,et al.  Structure and Mechanical Properties of Resistance Arteries in Hypertension: Role of Adhesion Molecules and Extracellular Matrix Determinants , 2000, Hypertension.

[8]  S. Takai,et al.  Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta , 1997, FEBS letters.

[9]  S. Takai,et al.  Inhibition of chymase reduces vascular proliferation in dog grafted veins , 2000, FEBS letters.

[10]  J. Connell,et al.  Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. , 1999, Circulation.

[11]  A. Ooshima,et al.  Proceedings: Developmental course of hypertension in the SHR-substrains susceptible to hypertensive cerebrovascular lesions. , 1974, Japanese heart journal.

[12]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[13]  H. Ju,et al.  A novel vascular smooth muscle chymase is upregulated in hypertensive rats. , 2001, The Journal of clinical investigation.

[14]  R. Touyz.  Molecular and cellular mechanisms regulating vascular function and structure--implications in the pathogenesis of hypertension. , 2000, The Canadian journal of cardiology.

[15]  K. Fang,et al.  Dog Mast Cell α-Chymase Activates Progelatinase B by Cleaving the Phe88-Gln89 and Phe91-Glu92 Bonds of the Catalytic Domain* , 1997, The Journal of Biological Chemistry.

[16]  A. Fukamizu,et al.  Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. , 1993, The Journal of biological chemistry.

[17]  J. Travis,et al.  Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. , 1985, Biochemical and biophysical research communications.

[18]  N. Katunuma,et al.  Chymotrypsin- and trypsin-type serine proteases in rat mast cells: properties and functions. , 1985, Archives of biochemistry and biophysics.

[19]  Shokei Kim,et al.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. , 2000, Pharmacological reviews.

[20]  Andrew R. Cherenson,et al.  The structure of an antigenic determinant in a protein , 1984, Cell.

[21]  J. Wiseman,et al.  Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. , 1992, Biochemical pharmacology.

[22]  P. Kovanen,et al.  Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder region of atheromas. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[23]  Christopher J. O’Callaghan,et al.  Mechanical Strain–Induced Extracellular Matrix Production by Human Vascular Smooth Muscle Cells: Role of TGF-&bgr;1 , 2000, Hypertension.

[24]  G. Di Luozzo,et al.  Vascular smooth muscle cell effect on endothelial cell endothelin-1 production. , 2000, Journal of vascular surgery.

[25]  D. Garbers,et al.  The molecular basis of hypertension. , 1999, Annual review of biochemistry.

[26]  K. Misono,et al.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.

[27]  A. Clowes,et al.  Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. , 1996, Circulation research.

[28]  R. Aldrich,et al.  Vasoregulation by the β1 subunit of the calcium-activated potassium channel , 2000, Nature.

[29]  R. Walsh,et al.  Effects of angiotensin II generated by an angiotensin converting enzyme-independent pathway on left ventricular performance in the conscious baboon. , 1995, The Journal of clinical investigation.

[30]  S. Takai,et al.  Characterization of chymase from human vascular tissues. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[31]  K. Suzuki,et al.  Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast-cell proteinases I and II. , 1995, The Biochemical journal.

[32]  R. Diegelmann,et al.  Cleavage of Type I Procollagen by Human Mast Cell Chymase Initiates Collagen Fibril Formation and Generates a Unique Carboxyl-terminal Propeptide* , 1997, The Journal of Biological Chemistry.

[33]  G. Angelini,et al.  Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[34]  A. Fukamizu,et al.  Activation of two angiotensin‐generating systems in the balloon‐injured artery , 1993, FEBS letters.

[35]  P. Jones,et al.  Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. , 2000, The Journal of clinical investigation.

[36]  M. Moskowitz,et al.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.